160 related articles for article (PubMed ID: 22231376)
1. Analysis of the pharmacodynamic activity of the mTOR inhibitor ridaforolimus (AP23573, MK-8669) in a phase 1 clinical trial.
Berk L; Mita MM; Kreisberg J; Bedrosian CL; Tolcher AW; Clackson T; Rivera VM
Cancer Chemother Pharmacol; 2012 May; 69(5):1369-77. PubMed ID: 22231376
[TBL] [Abstract][Full Text] [Related]
2. Phase IB study of the mTOR inhibitor ridaforolimus with capecitabine.
Perotti A; Locatelli A; Sessa C; Hess D; Viganò L; Capri G; Maur M; Cerny T; Cresta S; Rojo F; Albanell J; Marsoni S; Corradino I; Berk L; Rivera VM; Haluska F; Gianni L
J Clin Oncol; 2010 Oct; 28(30):4554-61. PubMed ID: 20855840
[TBL] [Abstract][Full Text] [Related]
3. Pharmacodynamic Evaluation of CCI-779, an Inhibitor of mTOR, in Cancer Patients.
Peralba JM; DeGraffenried L; Friedrichs W; Fulcher L; Grünwald V; Weiss G; Hidalgo M
Clin Cancer Res; 2003 Aug; 9(8):2887-92. PubMed ID: 12912932
[TBL] [Abstract][Full Text] [Related]
4. Ridaforolimus for patients with progressive or recurrent malignant glioma: a perisurgical, sequential, ascending-dose trial.
Reardon DA; Wen PY; Alfred Yung WK; Berk L; Narasimhan N; Turner CD; Clackson T; Rivera VM; Vogelbaum MA
Cancer Chemother Pharmacol; 2012 Apr; 69(4):849-60. PubMed ID: 22037923
[TBL] [Abstract][Full Text] [Related]
5. Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition.
Dudkin L; Dilling MB; Cheshire PJ; Harwood FC; Hollingshead M; Arbuck SG; Travis R; Sausville EA; Houghton PJ
Clin Cancer Res; 2001 Jun; 7(6):1758-64. PubMed ID: 11410517
[TBL] [Abstract][Full Text] [Related]
6. Ridaforolimus (AP23573; MK-8669), a potent mTOR inhibitor, has broad antitumor activity and can be optimally administered using intermittent dosing regimens.
Rivera VM; Squillace RM; Miller D; Berk L; Wardwell SD; Ning Y; Pollock R; Narasimhan NI; Iuliucci JD; Wang F; Clackson T
Mol Cancer Ther; 2011 Jun; 10(6):1059-71. PubMed ID: 21482695
[TBL] [Abstract][Full Text] [Related]
7. Multimodal biomarker investigation on efficacy and mechanism of action for the mammalian target of rapamycin inhibitor, temsirolimus, in a preclinical mammary carcinoma OncoMouse model: a translational medicine study in support for early clinical development.
Wang X; Zhan Y; Zhao L; Alvarez J; Chaudhary I; Zhou BB; Abraham RT; Feuerstein GZ
J Pharmacol Exp Ther; 2011 Nov; 339(2):421-9. PubMed ID: 21835932
[TBL] [Abstract][Full Text] [Related]
8. Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data.
Tanaka C; O'Reilly T; Kovarik JM; Shand N; Hazell K; Judson I; Raymond E; Zumstein-Mecker S; Stephan C; Boulay A; Hattenberger M; Thomas G; Lane HA
J Clin Oncol; 2008 Apr; 26(10):1596-602. PubMed ID: 18332467
[TBL] [Abstract][Full Text] [Related]
9. Sustained antitumor activity by co-targeting mTOR and the microtubule with temsirolimus/vinblastine combination in hepatocellular carcinoma.
Zhou Q; Lui VW; Lau CP; Cheng SH; Ng MH; Cai Y; Chan SL; Yeo W
Biochem Pharmacol; 2012 May; 83(9):1146-58. PubMed ID: 22285225
[TBL] [Abstract][Full Text] [Related]
10. Phase Ib study of weekly mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) with weekly paclitaxel.
Sessa C; Tosi D; Viganò L; Albanell J; Hess D; Maur M; Cresta S; Locatelli A; Angst R; Rojo F; Coceani N; Rivera VM; Berk L; Haluska F; Gianni L
Ann Oncol; 2010 Jun; 21(6):1315-1322. PubMed ID: 19901013
[TBL] [Abstract][Full Text] [Related]
11. Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer models.
Gozgit JM; Squillace RM; Wongchenko MJ; Miller D; Wardwell S; Mohemmad Q; Narasimhan NI; Wang F; Clackson T; Rivera VM
Cancer Chemother Pharmacol; 2013 May; 71(5):1315-23. PubMed ID: 23468082
[TBL] [Abstract][Full Text] [Related]
12. Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies.
Mita MM; Mita AC; Chu QS; Rowinsky EK; Fetterly GJ; Goldston M; Patnaik A; Mathews L; Ricart AD; Mays T; Knowles H; Rivera VM; Kreisberg J; Bedrosian CL; Tolcher AW
J Clin Oncol; 2008 Jan; 26(3):361-7. PubMed ID: 18202410
[TBL] [Abstract][Full Text] [Related]
13. Acetaldehyde promotes rapamycin-dependent activation of p70(S6K) and glucose uptake despite inhibition of Akt and mTOR in dopaminergic SH-SY5Y human neuroblastoma cells.
Fang CX; Yang X; Sreejayan N; Ren J
Exp Neurol; 2007 Jan; 203(1):196-204. PubMed ID: 16962100
[TBL] [Abstract][Full Text] [Related]
14. Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy.
Demetri GD; Chawla SP; Ray-Coquard I; Le Cesne A; Staddon AP; Milhem MM; Penel N; Riedel RF; Bui-Nguyen B; Cranmer LD; Reichardt P; Bompas E; Alcindor T; Rushing D; Song Y; Lee RM; Ebbinghaus S; Eid JE; Loewy JW; Haluska FG; Dodion PF; Blay JY
J Clin Oncol; 2013 Jul; 31(19):2485-92. PubMed ID: 23715582
[TBL] [Abstract][Full Text] [Related]
15. Rapamycin inhibits cell motility by suppression of mTOR-mediated S6K1 and 4E-BP1 pathways.
Liu L; Li F; Cardelli JA; Martin KA; Blenis J; Huang S
Oncogene; 2006 Nov; 25(53):7029-40. PubMed ID: 16715128
[TBL] [Abstract][Full Text] [Related]
16. Phase I/IIa trial of the mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) administered orally in patients with refractory or advanced malignancies and sarcoma.
Mita MM; Poplin E; Britten CD; Tap WD; Rubin EH; Scott BB; Berk L; Rivera VM; Loewy JW; Dodion P; Haluska F; Sarantopoulos J; Mita A; Tolcher A
Ann Oncol; 2013 Apr; 24(4):1104-11. PubMed ID: 23211938
[TBL] [Abstract][Full Text] [Related]
17. Ridaforolimus: a promising drug in the treatment of soft-tissue sarcoma and other malignancies.
Dancey JE; Monzon J
Future Oncol; 2011 Jul; 7(7):827-39. PubMed ID: 21732754
[TBL] [Abstract][Full Text] [Related]
18. Incomplete inhibition of phosphorylation of 4E-BP1 as a mechanism of primary resistance to ATP-competitive mTOR inhibitors.
Ducker GS; Atreya CE; Simko JP; Hom YK; Matli MR; Benes CH; Hann B; Nakakura EK; Bergsland EK; Donner DB; Settleman J; Shokat KM; Warren RS
Oncogene; 2014 Mar; 33(12):1590-600. PubMed ID: 23542178
[TBL] [Abstract][Full Text] [Related]
19. The rapamycin-sensitive signal transduction pathway as a target for cancer therapy.
Hidalgo M; Rowinsky EK
Oncogene; 2000 Dec; 19(56):6680-6. PubMed ID: 11426655
[TBL] [Abstract][Full Text] [Related]
20. Assay validation of phosphorylated S6 ribosomal protein for a pharmacodynamic monitoring of mTOR-inhibitors in peripheral human blood.
Dieterlen MT; Bittner HB; Klein S; von Salisch S; Mittag A; Tárnok A; Dhein S; Mohr FW; Barten MJ
Cytometry B Clin Cytom; 2012 May; 82(3):151-7. PubMed ID: 22213594
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
